{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:27Z","timestamp":1793892747366,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,20]]},"DOI":"10.1038\/s41416-026-03581-0","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:43:20Z","timestamp":1788198200000},"page":"1743-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-5728","authenticated-orcid":false,"given":"Alba","family":"Zuidema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-788X","authenticated-orcid":false,"given":"Kyah","family":"van Megesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Marit","family":"Vosjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan J.","family":"Viergever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-4390","authenticated-orcid":false,"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7982","authenticated-orcid":false,"given":"Richard P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"3581_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"3581_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69:438\u201347.","journal-title":"Eur Urol"},{"key":"3581_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JU.0000000000000593","volume":"203","author":"CR Ritch","year":"2020","unstructured":"Ritch CR, Velasquez MC, Kwon D, Becerra MF, Soodana-Prakash N, Atluri VS, et al. Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203:505\u201311.","journal-title":"J Urol"},{"key":"3581_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41571-025-01104-z","volume":"23","author":"MP St-Laurent","year":"2026","unstructured":"St-Laurent MP, Nikkola J, Tomiyama E, Black PC. Advances in the management of localized bladder cancers. Nat Rev Clin Oncol. 2026;23:158\u201379.","journal-title":"Nat Rev Clin Oncol"},{"key":"3581_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278\u201393.","journal-title":"Nat Rev Clin Oncol"},{"key":"3581_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nrm1493","volume":"5","author":"J Bartek","year":"2004","unstructured":"Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 2004;5:792\u2013804.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3581_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3581_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18:586\u201395.","journal-title":"Nat Rev Cancer"},{"key":"3581_CR9","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.18632\/oncotarget.6482","volume":"7","author":"CC Li","year":"2016","unstructured":"Li CC, Yang JC, Lu MC, Lee CL, Peng CY, Hsu WY, et al. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. Oncotarget. 2016;7:1947\u201359.","journal-title":"Oncotarget"},{"key":"3581_CR10","doi-asserted-by":"publisher","first-page":"e0266476","DOI":"10.1371\/journal.pone.0266476","volume":"17","author":"M Isono","year":"2022","unstructured":"Isono M, Okubo K, Asano T, Sato A. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells. PLoS ONE. 2022;17:e0266476.","journal-title":"PLoS ONE"},{"key":"3581_CR11","doi-asserted-by":"crossref","unstructured":"Chughtai AA, Pannhausen J, Dinger P, Wirtz J, Knuchel R, Gaisa NT, et al. Effective radiosensitization of bladder cancer cells by pharmacological inhibition of DNA-PK and ATR. Biomedicines. 2022;10:1277.","DOI":"10.3390\/biomedicines10061277"},{"key":"3581_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.32604\/or.2024.048919","volume":"32","author":"H Kim","year":"2024","unstructured":"Kim H, Cho U, Hong SH, Park HS, Kim IH, An HJ, et al. New insights into ATR inhibition in muscle invasive bladder cancer: the role of apolipoprotein B mRNA editing catalytic subunit 3B. Oncol Res. 2024;32:1021\u201330.","journal-title":"Oncol Res"},{"key":"3581_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clgc.2022.10.016","volume":"21","author":"RC Leibrandt","year":"2023","unstructured":"Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. ATR inhibition in advanced urothelial carcinoma. Clin Genitourin Cancer. 2023;21:203\u20137.","journal-title":"Clin Genitourin Cancer"},{"key":"3581_CR14","doi-asserted-by":"crossref","unstructured":"van Megesen K, Stefan A, Kieboom M, Amico R, Jansen AML, Borel Rinkes I, et al. Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C. Br J Cancer. 2026134:831\u201342.","DOI":"10.1038\/s41416-025-03310-z"},{"key":"3581_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.euf.2022.07.006","volume":"8","author":"YS Kim","year":"2022","unstructured":"Kim YS, Hsieh AC, Lam HM. Bladder cancer patient-derived organoids and avatars for personalized cancer discovery. Eur Urol Focus. 2022;8:657\u20139.","journal-title":"Eur Urol Focus"},{"key":"3581_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euf.2024.08.008","volume":"11","author":"M Radic","year":"2025","unstructured":"Radic M, Egger M, Kruithof-de Julio M, Seiler R. Patient-derived organoids in bladder cancer: opportunities and challenges. Eur Urol Focus. 2025;11:62\u201370.","journal-title":"Eur Urol Focus"},{"key":"3581_CR17","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel H, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci USA. 2019;116:4567\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3581_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","volume":"130","author":"BJ Viergever","year":"2024","unstructured":"Viergever BJ, Raats DAE, Geurts V, Mullenders J, Jonges TN, van der Heijden MS, et al. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. Br J Cancer. 2024;130:369\u201379.","journal-title":"Br J Cancer"},{"key":"3581_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022;20:587\u201396.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"3581_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"3581_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"3581_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","volume":"16","author":"S Berg","year":"2019","unstructured":"Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, et al. ilastik: interactive machine learning for (bio)image analysis. Nat Methods. 2019;16:1226\u201332.","journal-title":"Nat Methods"},{"key":"3581_CR23","doi-asserted-by":"crossref","unstructured":"Jung M, Jang I, Kim K, Moon KC. Non-muscle-invasive bladder carcinoma with respect to basal versus luminal keratin expression. Int J Mol Sci. 2020;21:7726.","DOI":"10.3390\/ijms21207726"},{"key":"3581_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27\u201342.","journal-title":"Cancer Cell"},{"key":"3581_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24:679\u201386.","journal-title":"Leukemia"},{"key":"3581_CR26","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020;38:3195\u2013204.","journal-title":"J Clin Oncol"},{"key":"3581_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","volume":"125","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125:520\u20137.","journal-title":"Br J Cancer"},{"key":"3581_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106:1404\u201314.","journal-title":"Br J Surg"},{"key":"3581_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107518","volume":"210","author":"L Gorecki","year":"2020","unstructured":"Gorecki L, Andrs M, Rezacova M, Korabecny J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol Ther. 2020;210:107518.","journal-title":"Pharmacol Ther"},{"key":"3581_CR30","doi-asserted-by":"publisher","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","volume":"14","author":"E Demidenko","year":"2019","unstructured":"Demidenko E, Miller TW. Statistical determination of synergy based on Bliss definition of drugs independence. PLoS ONE. 2019;14:e0224137.","journal-title":"PLoS ONE"},{"key":"3581_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2020.101893","volume":"31","author":"T Nakayama","year":"2020","unstructured":"Nakayama T, Nozawa N, Kawada C, Yamamoto S, Ishii T, Ishizuka M, et al. Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. Photodiagnosis Photodyn Ther. 2020;31:101893.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"3581_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","volume":"23","author":"U Jo","year":"2024","unstructured":"Jo U, Arakawa Y, Zimmermann A, Taniyama D, Mizunuma M, Jenkins LM, et al. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs. Mol Cancer Ther. 2024;23:911\u201323.","journal-title":"Mol Cancer Ther"},{"key":"3581_CR33","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem. 2018;61:9889\u2013907.","journal-title":"J Med Chem"},{"key":"3581_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-06-0633","volume":"6","author":"B Ewald","year":"2007","unstructured":"Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther. 2007;6:1239\u201348.","journal-title":"Mol Cancer Ther"},{"key":"3581_CR35","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1124\/mol.105.012716","volume":"68","author":"LM Karnitz","year":"2005","unstructured":"Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol. 2005;68:1636\u201344.","journal-title":"Mol Pharmacol"},{"key":"3581_CR36","doi-asserted-by":"publisher","DOI":"10.31083\/FBL46326","volume":"30","author":"Z Nan","year":"2025","unstructured":"Nan Z, Wang X, Wang Y, Cui Y, Fang B. Epirubicin induces cell cycle arrest in multiple myeloma cells by downregulating CDC20 expression. Front Biosci. 2025;30:46326.","journal-title":"Front Biosci"},{"key":"3581_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s10495-018-1450-2","volume":"23","author":"TC Huang","year":"2018","unstructured":"Huang TC, Chiu PR, Chang WT, Hsieh BS, Huang YC, Cheng HL, et al. Epirubicin induces apoptosis in osteoblasts through death-receptor and mitochondrial pathways. Apoptosis. 2018;23:226\u201336.","journal-title":"Apoptosis"},{"key":"3581_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1074\/jbc.M106287200","volume":"277","author":"WA Cliby","year":"2002","unstructured":"Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem. 2002;277:1599\u2013606.","journal-title":"J Biol Chem"},{"key":"3581_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/(SICI)1097-0320(19971201)29:4<321::AID-CYTO9>3.0.CO;2-C","volume":"29","author":"IA Hedenfalk","year":"1997","unstructured":"Hedenfalk IA, Baldetorp B, Borg A, Oredsson SM. Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry. Cytometry. 1997;29:321\u20137.","journal-title":"Cytometry"},{"key":"3581_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114109","volume":"230","author":"B Cheng","year":"2022","unstructured":"Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur J Med Chem. 2022;230:114109.","journal-title":"Eur J Med Chem"},{"key":"3581_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547\u201360.","journal-title":"Mol Cell"},{"key":"3581_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"key":"3581_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/13543784.2017.1389895","volume":"26","author":"I Brandsma","year":"2017","unstructured":"Brandsma I, Fleuren EDG, Williamson CT, Lord CJ. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017;26:1341\u201355.","journal-title":"Expert Opin Investig Drugs"},{"key":"3581_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515\u201328.e17.","journal-title":"Cell"},{"key":"3581_CR45","doi-asserted-by":"crossref","unstructured":"Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg OW, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. Npj Precis Oncol. 2021;5:30.","DOI":"10.1038\/s41698-021-00168-1"},{"key":"3581_CR46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21:571\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3581_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat Commun. 2023;14:2214.","journal-title":"Nat Commun"},{"key":"3581_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","volume":"86","author":"NM Merrill","year":"2024","unstructured":"Merrill NM, Kaffenberger SD, Bao L, Vandecan N, Goo L, Apfel A, et al. Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response. Eur Urol. 2024;86:434\u201344.","journal-title":"Eur Urol"},{"key":"3581_CR49","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165:1586\u201397.","journal-title":"Cell"},{"key":"3581_CR50","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","volume":"7","author":"SK Pal","year":"2021","unstructured":"Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, et al. Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7:1536\u201343.","journal-title":"JAMA Oncol"},{"key":"3581_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00635","volume":"8","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos PA, Cheng SC, Lee EK, da Costa A, Gulhan D, Wahner Hendrickson AE, et al. Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses. JCO Precis Oncol. 2024;8:e2300635.","journal-title":"JCO Precis Oncol"},{"key":"3581_CR52","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, et al. First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res. 2024;30:2057\u201367.","journal-title":"Clin Cancer Res"},{"key":"3581_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"key":"3581_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29:71.","journal-title":"J Biomed Sci"},{"key":"3581_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217506","volume":"614","author":"MP Scholtes","year":"2025","unstructured":"Scholtes MP, Akbarzadeh M, Galaras A, Nakauma-Gonzales JA, Bazrafshan A, Solanki V, et al. Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets. Cancer Lett. 2025;614:217506.","journal-title":"Cancer Lett"},{"key":"3581_CR56","doi-asserted-by":"crossref","unstructured":"Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bogemann M, Simone G, et al. TAR-200 for bacillus calmette-guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J Clin Oncol. 2025;43:3578\u201388.","DOI":"10.1200\/JCO-25-02053"},{"key":"3581_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59\u201373.","journal-title":"Nat Rev Immunol"},{"key":"3581_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2447403","volume":"57","author":"G Li","year":"2025","unstructured":"Li G, Che X, Wang S, Liu D, Xie D, Jiang B, et al. The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy. Ann Med. 2025;57:2447403.","journal-title":"Ann Med"},{"key":"3581_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104702","volume":"210","author":"D Liu","year":"2025","unstructured":"Liu D, Liu L, Zhao X, Zhang X, Chen X, Che X, et al. A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors. Crit Rev Oncol Hematol. 2025;210:104702.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03581-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:53:12Z","timestamp":1793890392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,20]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03581-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPM reports advisory role (institutional): Merck B.V., Astellas; research support (institutional): Merck B.V., Janssen\u2013Cilag B.V., Astellas, Gilead Sciences Netherlands B.V.; speaker honoraria: Astellas; Ismar Healthcare NV.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}